GRCE (Grace Therapeutics) FFO


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.36
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

GRCE
31GF Score
Grace Therapeutics Inc GRCE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price